Generex Biotechnology Corporation (OTCMKTS:GNBT) is a micro-cap biotech name that has recently started to rip higher out of sub-penny territory and into the light of day. We think this movement likely stems from some positives falling into place at the company’s key subsidiary, Hema Diagnostic Systems. Hema just announced the availability of the new RAPID 1-2-3 HEMA EXPRESS HIV 1/2 P24Ab 4th Generation rapid diagnostic test for HIV. The RAPID 1-2-3 HEMA EXPRESS HIV 1/2 P24Ab includes GP36, GP41, subtype “O” and the ability to detect the HIV P24 Antibody (Ab), enabling reduced HIV detection time.
According the company’s most recent press release, “the RAPID 1-2-3 HEMA EXPRESS HIV 1/2 P24Ab uses whole blood, serum, or plasma as a test sample with test results appearing as quickly as 10 minutes. Through its simple, user-friendly design, the RAPID 1-2-3 HEMA EXPRESS HIV 1/2 P24Ab eliminates many of the difficulties generally associated with rapid cassette testing, including the uncontrolled transfer of a potentially infected test sample. The sample pad of the EXPRESS device has an easily visible “minimum blood” volume line, making it easy to determine when a sufficient test sample has been taken up and into the test. Additionally, the guess work, normally associated with adding diluent, has also been eliminated, as the diluent pod of the RAPID 1-2-3 HEMA EXPRESS HIV P24Ab contains the exact, premeasured diluent volume necessary to run the diagnostic.”
Generex Biotechnology Corporation (OTCMKTS:GNBT) trumpets itself as a company engaged in the research, development, and commercialization of drug delivery systems and technologies.
As the company states, Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex.
The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.
According to company materials, “Hema Diagnostic Systems, LLC (www.rapid123.com) is a rapidly growing biotechnology company involved in the development, manufacture, assembly, and distribution of diagnostics targeting primary as well as orphan infectious diseases. Hema Diagnostic Systems continues to expand its product line to meet the needs of the worldwide market. Point-of-Care test devices are made simple to use and are highly cost effective when incorporated into Hema Diagnostic Systems’ patented and patent pending delivery systems. The Rapid 1-2-3 Hema EXPRESS® is a novel delivery system that is self-contained and easy to use.”
Find out when $GNBT stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
“Our concept in designing the EXPRESS device was based upon a simple, easy-to-use and user-friendly system. HDS added the P24Ab detection to our product mix to give our clients the ability to detect the presence of HIV earlier than non-P24Ab tests without sacrificing the ability to deliver exceptional Sensitivity and Specificity results,” said Lawrence Salvo, President and CEO of Hema Diagnostic Systems.
Salvo further added: “While our current antibody test is effective, we felt that the market required a cost-effective P24Ab version. The test is designed for field use in the developing world, so it is durable, easy-to-use, safe, and most importantly provides near immediate results – perfect for community-based screening. Our RAPID 1-2-3® HEMA® EXPRESS HIV P24Ab is expected to be a most welcome member of our expanding array of HDS rapid tests.”
Recent action has seen more than 160% tacked on to share pricing for the name in the past month, a bounce that has taken root amid largely bearish action over the larger time frame. The situation may be worth watching. GNBT has evidenced sudden upward volatility on many prior occasions. Furthermore, the listing has benefitted from a jump in recent trading volume to the tune of topping 350% above its longer-run average levels.
Earning a current market cap value of $10M, GNBT has virtually no cash on the books, which compares with virtually no total current liabilities. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. You can bet we will update this one again as new information comes into view. For continuing coverage on shares of $GNBT stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!